A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405

Alzheimer's Disease

COMPLETED PHASE1

A Safety Study of LY2811376 Single Doses in Healthy Subjects

NCT00838084

Alzheimer's Disease

COMPLETED PHASE1

A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease

NCT01807026

Alzheimer Disease Healthy Volunteers

COMPLETED PHASE1

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT06657768

Alzheimer Disease Healthy

RECRUITING PHASE1

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

NCT00329082

Alzheimer's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY2886721

Group Type EXPERIMENTAL

LY2886721

Intervention Type DRUG

5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally as capsules, daily for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2886721

5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days

Intervention Type DRUG

Placebo

Administered orally as capsules, daily for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy men and non-childbearing potential women
* Body mass index between 18.0-32.0 kilograms per square meter (kg/m\^2)
* Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies

Exclusion Criteria

* Taking over-the-counter or prescription medication with the exception of vitamins or minerals
* Smoke more than 10 cigarettes per day
* Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes